Apichope Pharmaceutical (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" for Olmesartan Medoxomil orally disintegrating tablets issued by the National Medical Products Administration. Olmesartan Medoxomil orally disintegrating tablets are used for the treatment of hypertension.

Obtaining the registration certificate for Olmesartan Medoxomil orally disintegrating tablets indicates that the company has the qualification to produce and sell the drug in the domestic market, which will further enrich the company's product pipeline and category in the field of chronic disease treatment, and enhance the company's competitiveness in the area of chronic disease drugs.